Kalberg CJ - Search Results

1

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A. Celli B, et al. Among authors: kalberg cj. Chest. 2014 May;145(5):981-991. doi: 10.1378/chest.13-1579. Chest. 2014. PMID: 24385182 Clinical Trial.

2

Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.

Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R. Goyal N, et al. Clin Pharmacokinet. 2014 Jul;53(7):637-48. doi: 10.1007/s40262-014-0143-4. Clin Pharmacokinet. 2014. PMID: 24756395

3

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Donohue JF, et al. Respir Med. 2013 Oct;107(10):1538-46. doi: 10.1016/j.rmed.2013.06.001. Epub 2013 Jul 2. Respir Med. 2013. PMID: 23830094 Free article. Clinical Trial.

4

Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.

Singh D, Zhu CQ, Sharma S, Church A, Kalberg CJ. Singh D, et al. Among authors: kalberg cj. Pulm Pharmacol Ther. 2015 Apr;31:85-91. doi: 10.1016/j.pupt.2014.08.010. Epub 2014 Sep 6. Pulm Pharmacol Ther. 2015. PMID: 25197005 Free article. Clinical Trial.

5

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.

Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA. Kerwin EM, et al. Among authors: kalberg cj. Int J Chron Obstruct Pulmon Dis. 2017 Feb 24;12:745-755. doi: 10.2147/COPD.S119032. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28280319 Free PMC article. Clinical Trial.

6

Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.

O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K. O'Donnell DE, et al. Among authors: kalberg cj. Chest. 2006 Sep;130(3):647-56. doi: 10.1378/chest.130.3.647. Chest. 2006. PMID: 16963658 Clinical Trial.

7

A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.

Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. Donohue JF, et al. Respir Med. 2012 Jul;106(7):970-9. doi: 10.1016/j.rmed.2012.03.012. Epub 2012 Apr 10. Respir Med. 2012. PMID: 22498110 Free article. Clinical Trial.

8

Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.

Donohue JF, Kalberg C, Shah P, Beerahee M, Mehta R, Gunawan R, Church A. Donohue JF, et al. J Clin Pharmacol. 2014 Nov;54(11):1214-20. doi: 10.1002/jcph.340. Epub 2014 Jun 24. J Clin Pharmacol. 2014. PMID: 24895108 Clinical Trial.

9

Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility.

Bleecker ER, Emmett A, Crater G, Knobil K, Kalberg C. Bleecker ER, et al. Pulm Pharmacol Ther. 2008 Aug;21(4):682-8. doi: 10.1016/j.pupt.2008.04.003. Epub 2008 May 1. Pulm Pharmacol Ther. 2008. PMID: 18541448

10

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.

Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Anzueto A, et al. COPD. 2009 Oct;6(5):320-9. doi: 10.1080/15412550903140881. COPD. 2009. PMID: 19863361 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters